Literature DB >> 25761572

Methods for surveillance of fetal alcohol syndrome: The Fetal Alcohol Syndrome Surveillance Network II (FASSNetII) - Arizona, Colorado, New York, 2009 - 2014.

Leslie A O'Leary1, Linnette Ortiz, April Montgomery, Deborah J Fox, Christopher Cunniff, Margaret Ruttenber, April Breen, Sydney Pettygrove, Don Klumb, Charlotte Druschel, Jaime L Frías, Luther K Robinson, Jacquelyn Bertrand, Kelly Ferrara, Maureen Kelly, Suzanne M Gilboa, F John Meaney.   

Abstract

Surveillance of fetal alcohol syndrome (FAS) is important for monitoring the effects of prenatal alcohol exposure and describing the public health burden of this preventable disorder. Building on the infrastructure of the Fetal Alcohol Syndrome Surveillance Network (FASSNet, 1997-2002), in 2009 the Centers for Disease Control and Prevention awarded 5-year cooperative agreements to three states, Arizona, Colorado, and New York, to conduct population-based surveillance of FAS. The Fetal Alcohol Syndrome Surveillance Network II (FASSNetII, 2009-2014) developed a surveillance case definition based on three clinical criteria: characteristic facial features, central nervous system abnormalities, and growth deficiency. FASSNetII modified the FASSNet methods in three important ways: (1) estimation of a period prevalence rather than birth prevalence; (2) surveillance of FAS among school-age children (ages 7-9 years) to better document the central nervous system abnormalities that are not apparent at birth or during infancy; and (3) implementation of an expert clinical review of abstracted data for probable and confirmed cases classified through a computerized algorithm. FASSNetII abstracted data from multiple sources including birth records, medical records from child development centers or other specialty clinics, and administrative databases such as hospital discharge and Medicaid. One challenge of FASSNetII was its limited access to non-medical records. The FAS prevalence that could be estimated was that of the population identified through an encounter with the healthcare system. Clinical and public health programs that identify children affected by FAS provide critical information for targeting preventive, medical and educational services in this vulnerable population.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  birth defects; clinical review; developmental disabilities; fetal alcohol syndrome; population-based surveillance

Mesh:

Year:  2015        PMID: 25761572      PMCID: PMC4484746          DOI: 10.1002/bdra.23335

Source DB:  PubMed          Journal:  Birth Defects Res A Clin Mol Teratol        ISSN: 1542-0752


  17 in total

1.  A multiple source methodology for the surveillance of fetal alcohol syndrome--The Fetal Alcohol Syndrome Surveillance Network (FASSNet).

Authors:  Karen Hymbaugh; Lisa A Miller; Charlotte M Druschel; Danise W Podvin; F John Meaney; Coleen A Boyle
Journal:  Teratology       Date:  2002

2.  United States head circumference growth reference charts: birth to 21 years.

Authors:  Jonathan D Rollins; Julianne S Collins; Kenton R Holden
Journal:  J Pediatr       Date:  2010-03-20       Impact factor: 4.406

Review 3.  Prevalence and epidemiologic characteristics of FASD from various research methods with an emphasis on recent in-school studies.

Authors:  Philip A May; J Phillip Gossage; Wendy O Kalberg; Luther K Robinson; David Buckley; Melanie Manning; H Eugene Hoyme
Journal:  Dev Disabil Res Rev       Date:  2009

4.  Palpebral fissure length from 29 weeks gestation to 14 years.

Authors:  I T Thomas; Y A Gaitantzis; J L Frias
Journal:  J Pediatr       Date:  1987-08       Impact factor: 4.406

5.  Pattern of malformation in offspring of chronic alcoholic mothers.

Authors:  K L Jones; D W Smith; C N Ulleland; P Streissguth
Journal:  Lancet       Date:  1973-06-09       Impact factor: 79.321

6.  Fetal alcohol syndrome--United States, 1979-1992.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1993-05-07       Impact factor: 17.586

7.  Intrauterine growth in length and head circumference as estimated from live births at gestational ages from 26 to 42 weeks.

Authors:  L O Lubchenco; C Hansman; E Boyd
Journal:  Pediatrics       Date:  1966-03       Impact factor: 7.124

8.  2000 CDC Growth Charts for the United States: methods and development.

Authors:  Robert J Kuczmarski; Cynthia L Ogden; Shumei S Guo; Laurence M Grummer-Strawn; Katherine M Flegal; Zuguo Mei; Rong Wei; Lester R Curtin; Alex F Roche; Clifford L Johnson
Journal:  Vital Health Stat 11       Date:  2002-05

9.  Fetal alcohol syndrome--Alaska, Arizona, Colorado, and New York, 1995-1997.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-05-24       Impact factor: 17.586

10.  Exploring the feasibility of using electronic health records in the surveillance of fetal alcohol syndrome.

Authors:  Craig Hansen; Marvin Adams; Deborah J Fox; Leslie A O'Leary; Jaime L Frías; Heather Freiman; F John Meaney
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2014-02-12
View more
  4 in total

1.  Recognition of clinical characteristics for population-based surveillance of fetal alcohol syndrome.

Authors:  Jennifer G Andrews; Maureen K Galindo; F John Meaney; Argelia Benavides; Linnette Mayate; Deborah Fox; Sydney Pettygrove; Leslie O'Leary; Christopher Cunniff
Journal:  Birth Defects Res       Date:  2018-01-25       Impact factor: 2.344

Review 2.  Substance Use in the Perinatal Period.

Authors:  Ariadna Forray; Dawn Foster
Journal:  Curr Psychiatry Rep       Date:  2015-11       Impact factor: 5.285

3.  Fetal alcohol syndrome among children aged 7-9 years - Arizona, Colorado, and New York, 2010.

Authors:  Deborah J Fox; Sydney Pettygrove; Christopher Cunniff; Leslie A O'Leary; Suzanne M Gilboa; Jacquelyn Bertrand; Charlotte M Druschel; April Breen; Luther Robinson; Linnette Ortiz; Jaime L Frías; Margaret Ruttenber; Donald Klumb; F John Meaney
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-01-30       Impact factor: 17.586

4.  Why are Birth Defects Surveillance Programs Important?

Authors:  Débora Gusmão Melo; Maria Teresa Vieira Sanseverino; Thanyse de Oliveira Schmalfuss; Mariela Larrandaburu
Journal:  Front Public Health       Date:  2021-11-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.